

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO FORM 1449</b>	Atty. Docket No. <b>1662/60903</b>	Serial No. <b>10/649,399</b>
	Applicant(s) <b>Dolitzky et al.</b>	
	Filing Date <b>August 26, 2003</b>	Group <b>1624</b>



### U. S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

\* - If pertinent

### FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
MW	0 885 223 B1	Dec. 23, 1998	Europe				
MW	WO 97/29108	Aug. 14, 1997	PCT				

\* Copy of reference is not enclosed because reference is cited in Search Report (copy of reference provided by International Searching Authority).

### OTHER DOCUMENTS

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	M. R. Harnden et al., Nucleosides & Nucleotides 9(4):499-513 (1990)
MW	John Halebian et al "Pharmaceutical Applications of Polymorphism"; Journal of Pharmaceutical Sciences, Vol. 58, No. 8, August 1969 - PP.911 - 929.
MW	John K. Halebian "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications"; Journal of Pharmaceutical Sciences, Vol. 64, No. 8, August 1975 - PP1269 - 1288.
MW	G. Michael Wall "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No.2, February 1986; PP 33-42.

EXAMINER	DATE CONSIDERED
<i>Mark Ban</i>	4/11/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.